Quris, an Israeli company that is developing an AI platform to predict what drug candidates will work in humans, raised $9 million in Seed funding.
The round was led by Dr. Judith Richter and Dr. Kobi Richter, professionals of cardiovascular intervention therapeutics, with participation from Moshe Yanai, a disruptive data-storage technology expert, and strategic angel investors.
The announcement of the funding coincided with the launch of its platform via a partnership with The New York Stem Cell Foundation (NYSCF) Research Institute.
Company: Quris Technologies LTD.
Round: Seed Round
Funding Month: October 2021
Lead Investors: Dr. Judith Richter and Dr. Kobi Richter
Additional Investors: Moshe Yanai
Company Website: https://www.quris.ai/
Software Category: Clinician prediction AI platform
About the Company: Quris is an artificial intelligence innovator that is disrupting the drug development process. Quris machine-learning bio-platform better predicts which drug candidates will safely work in humans, avoiding the tremendous costs of failed clinical trials. Quris is led by a track-record team of top scientists and strategic investors. Its first AI-based drug is now prepping for clinical testing. The company currently has 18 granted and pending patents to help its platform use a combination of ‘minitarised biology’ chips and real-time nano-sensor and nano-circulation chips to train the Quris AI engine and drug candidate safety predictor.